Legend Biotech Corp (LEGN) Return on equity 2020–2024
Legend Biotech Corp (LEGN) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-17.0%FY2024 · since FY2020: -44.6% → -17.0%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2024 | -17.0% | +24.4 pp |
| FY2023 | -41.4% | +18.6 pp |
| FY2022 | -60.0% | -7.3 pp |
| FY2021 | -52.7% | -8.1 pp |
| FY2020 | -44.6% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More LEGN financial trends
LEGN RevenueLEGN Net incomeLEGN Net marginLEGN Gross profitLEGN Gross marginLEGN Operating incomeLEGN Operating marginLEGN Operating cash flowLEGN Free cash flowLEGN Capital expendituresLEGN Stock buybacksLEGN Dividends paidLEGN Total assetsLEGN Total liabilitiesLEGN Shareholders’ equityLEGN overview →